This human HPS3 knockout product is a polyclonal cell population derived from the A-549 lung adenocarcinoma cell line, engineered using CRISPR/Cas9-mediated gene disruption to eliminate functional HPS3 expression. The polyclonal format represents a diverse pool of edited cells, providing a robust loss-of-function model for investigating the cellular roles of HPS3 without clonal selection biases. The use of CRISPR/Cas9 technology ensures targeted disruption of the HPS3 locus, enabling researchers to study the consequences of HPS3 deficiency in a physiologically relevant epithelial context. This knockout model is designed for advanced applications in cell biology, cancer research, and organelle trafficking studies.
The A-549 host cell line was originally established from a 58-year-old male with lung carcinoma and is widely employed as a model of type II alveolar epithelial cells. These adherent epithelial cells are a cornerstone in cancer biology investigations, particularly for studying adenocarcinoma progression, drug metabolism, and responses to chemotherapeutic agents. The A-549 line retains key features of alveolar epithelium, including surfactant production and metabolic enzyme activities, making it a valuable platform for pulmonary disease modeling. In the context of HPS3 knockout, this background enables the exploration of lysosome-related organelle biogenesis within a lung-derived epithelial environment, offering insights into pulmonary manifestations of Hermansky-Pudlak syndrome.
At the molecular level, HPS3 encodes a subunit of the biogenesis of lysosome-related organelles complex-2 (BLOC-2), which also includes HPS5 and HPS6. This complex functions in protein sorting from early endosomes to lysosome-related organelles, a process that requires interactions with the AP-3 complex, clathrin, and various Rab GTPases. HPS3 activity is regulated by upstream factors including MITF and Wnt signaling, and it mediates the proper trafficking of downstream cargo such as TYRP1 for melanosome maturation and components of platelet dense granules. Disruption of HPS3 impairs the biogenesis of melanosomes, platelet dense granules, and other lysosome-related organelles, leading to the phenotypes observed in Hermansky-Pudlak syndrome type 3, including oculocutaneous albinism and bleeding diathesis.
The integration of HPS3 knockout into A-549 cells creates a distinctive model for dissecting the intersection of organelle trafficking defects and lung cancer biology. Hermansky-Pudlak syndrome type 3 is associated with pulmonary fibrosis, a progressive lung disease with limited treatment options. This model facilitates the investigation of how HPS3 loss influences alveolar epithelial cell function, potentially contributing to fibrotic pathways. Furthermore, because A-549 cells are frequently used in drug metabolism and toxicity studies, the knockout enables examination of how endosomal and lysosomal disruptions alter drug processing and sensitivity. The polyclonal nature of the knockout population also allows for the assessment of heterogeneous cellular responses, closely reflecting the complexity of tumor environments.
This HPS3 knockout polyclonal cell product supports a broad range of research applications. It is ideally suited for validating target-gene disruption via RT-qPCR and Western blotting of BLOC-2 components. Immunofluorescence microscopy can be employed to visualize organelle marker distribution, such as LAMP1 for lysosomes, while flow cytometry enables quantitative analysis of lysosomal proteins. Functional studies may include migration and invasion assays to assess metastatic potential, as well as drug sensitivity profiling to uncover HPS3-dependent chemotherapeutic responses. The model is applicable to investigations of Hermansky-Pudlak syndrome type 3, melanosome biogenesis, platelet dense granule formation, and pulmonary fibrosis, offering a versatile tool for both basic and translational research. For additional information or to inquire about ordering, please contact Ascent Research.
